Arvinas ARVN
- Market cap
- $491.7M
- PE
- 47.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $316.7M
- −15% on a year ago
- Net margin
- 2.9%
- Free cash flow yield
- −42.5%
Arvinas trades at 47.0× trailing earnings. Revenue was $316.7M over the last twelve months, down 15% on a year earlier with a 3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $34.6M+4% | n/a | $25.3M−22% | $76.5M+40% | $102.4M+196% | $59.2M | $188.8M+646% | $22.4M−71% | $41.9M−59% | $9.5M−84% | $15.6M−92% | $249.7M+1015% | |
| R&D | $85.9M+11% | n/a | $84.3M−12% | $93.7M−9% | $86.9M+1% | $83.3M | $90.8M+8% | $68.6M−27% | $64.7M−26% | $61.1M−27% | $60.3M−34% | $52.6M−23% |
| SG&A | $22.6M+13% | n/a | $24.3M−2% | $31.3M+22% | $75.8M+235% | $34.1M | $26.6M+10% | $25.3M−19% | $21M−72% | $23M−33% | $19.1M−28% | $24M−5% |
| −$73.9M+15% | n/a | −$83.3M−5% | −$48.5M−35% | −$60.3M−18% | −$58.2M | $71.4M | −$71.5M+47% | −$43.8M−27% | −$74.6M+28% | −$63.8M | $164.1M | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | n/a | $0 |
| Pre-tax income | −$63.9M+5% | n/a | −$69.3M−15% | −$35M−47% | −$48.6M−24% | −$45.5M | $83.1M | −$61.5M+76% | −$34.8M−28% | −$67.2M+48% | −$57.5M | $169.6M |
| $0 | n/a | $100K | $200K | $600K | −$400K | $200K+100% | −$300K | $300K−50% | $200K | $100K−50% | $200K | |
| Net income | −$64M−3% | −$154.8M+87% | −$69.4M−15% | −$35.2M−47% | −$49.2M−23% | −$45.1M−71% | $82.9M | −$61.2M+74% | −$35.1M−29% | −$67.4M+49% | −$57.6M | $169.4M |
| −$1.18−5% | −$2.53+63% | −$0.97−37% | −$0.49−61% | −$0.68−42% | −$0.63−75% | $1.14 | −$0.84+71% | −$0.48−29% | −$1.04+65% | −$0.90 | $2.58 | |
| 54.1M+2% | 61.1M+14% | 71.7M+35% | 71.9M+35% | 72.1M+33% | 71.9M+18% | 72.7M+1% | 73M+2% | 73.2M+2% | 65M−10% | 64M−12% | 65.7M−10% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Arvinas' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| Peer median | $685.3M | 11.3× | 13.5× | 1.5× | +14% | 22.5% |
More on Arvinas
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .